CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences

Citation
Wj. Tamminga et al., CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences, EUR J CL PH, 55(3), 1999, pp. 177-184
Citations number
23
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
ISSN journal
00316970 → ACNP
Volume
55
Issue
3
Year of publication
1999
Pages
177 - 184
Database
ISI
SICI code
0031-6970(199905)55:3<177:CACAIA>2.0.ZU;2-7
Abstract
Objective: We examined a large database containing results on CYP2D6 and CY P2C19 activity of 4301 Dutch volunteers phenotyped in the context of variou s clinical pharmacology studies. Methods: The subjects were given 22 mg dextromethorphan, 100 mg mephenytoin and 200 mg caffeine. For CYP2D6, the dextromethorphan/dextrorphan metaboli c ratios in urine samples taken for a subsequent 8 h were used. Dextrometho rphan and dextrorphan were quantified by reversed-phase high performance li quid chromatography. For CYP2C19 similarly obtained (R)-mephenytoin and (S) -mephenytoin ratios were used. (S)-mephenytoin and (R)-mephenytoin were ana lysed and quantified by enantioselective capillary gas chromatography. In a ddition, CYP2C19 poor metabolizer (PM) subjects were reanalysed after acidi c pre-treatment of urine samples to confirm the PM status. Results: The investigated population mainly comprised Caucasian (98.9%) mal es (68%). The age ranged from 18 to 82 years. For CYP2D6, it was found that 8.0% of the subjects were PMs. The average metabolic ratio was 0.014 (0.03 3) for subjects who showed extensive metabolizing activity (EM) and 5.4 (7. 6) for PM subjects. For CYP2C19, it was found that 1.8% of the subjects wer e PMs. The metabolic ratio was 0.162 (0.124) for EM subjects and 1.076 (0.0 40) for PM subjects. Within the EM group the metabolic ratio in females was significantly lower for CYP2D6 (-20%) and significantly higher for CYP2C19 (+40%) compared with males. For PMs there was no such difference for CYP2D 6 (P = 0.79) or CYP2C19 (P = 0.20). Oral contraceptive (OC) use significant ly decreased the CYP2C19 activity by 68% for mephenytoin as compared to non -OC using females. Conclusions: For CYP2D6, the PM incidence (8.0%) is in accordance with lite rature data. The CYP2C19, PM incidence (1.8%) is low compared to reports fr om other European countries. For mephenytoin, the acidification procedure h as been shown to be very important for the confirmation of CYP2C19 PMs. In EM females compared to EM males, CYP2D6 activity is increased and CYP2C19 a ctivity is reduced. For CYP2C19 in particular this reduction is substantial and most pronounced in the age range from 18 to 40 years. For CYP2C19, the reduced activity is associated with the use of oral contraceptives.